Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
Targets |
NF-κB
|
---|---|
ln Vitro |
Zingerone is a non-toxic methoxyphenol that has powerful anti-inflammatory, anti-diabetic, anti-lipolytic, anti-diarrheic, and antispasmodic properties[1].
Zingerone (0–2 mM) reduces neoblastoma cell survival[3]. Zingerone (0–2 mM) decreases cyclin D1 expression and increases caspase-3 and PARP-1 cleavage in BE(2)-M17 cells[3]. |
ln Vivo |
Zingerone (50, 100 mg/kg, p.o. daily for 21 days) protects against alloxan-induced diabetes in rats by reducing oxidative stress and inflammation[2].
Zingerone (10 mg/kg, i.p.) slows the growth of tumors by stopping the mitotic cycle, preventing cell division, and inducing apoptosis[3]. |
References |
|
Molecular Formula |
C11H14O3
|
---|---|
Molecular Weight |
194.23
|
Exact Mass |
194.0943
|
Elemental Analysis |
C, 68.02; H, 7.27; O, 24.71
|
CAS # |
122-48-5
|
Related CAS # |
122-48-5
|
Appearance |
Solid powder
|
SMILES |
CC(=O)CCC1=CC(=C(C=C1)O)OC
|
InChi Key |
OJYLAHXKWMRDGS-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C11H14O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h5-7,13H,3-4H2,1-2H3
|
Chemical Name |
4-(4-hydroxy-3-methoxyphenyl)butan-2-one
|
Synonyms |
Gingerone; Zingerone; AI331837; AI3 31837; AI3-31837
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 38~100 mg/mL (195.6~514.9 mM)
Water: ~10 mg/mL (~51.5 mM) Ethanol: ~38 mg/mL (~195.6 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.1485 mL | 25.7427 mL | 51.4854 mL | |
5 mM | 1.0297 mL | 5.1485 mL | 10.2971 mL | |
10 mM | 0.5149 mL | 2.5743 mL | 5.1485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05779280 | Active Recruiting |
Other: THDA + Acetyl Zingerone Topical Product Other: THDA |
Wrinkle Skin Pigmentation |
Integrative Skin Science and Research |
April 6, 2023 | Not Applicable |
NCT03530787 | Completed | Other: Acetyl Zingerone Topical Cream Other: Topical cream |
Wrinkle Appearance Skin Pigment |
University of California, Davis | December 11, 2017 | Not Applicable |
Chemical structure of zingerone. IUPAC name: [4-(3-methoxy-4-hydroxyphenyl)-butan-2-one]. ScientificWorldJournal . 2015:2015:816364. td> |
Pharmacological dimensions of zingerone. ScientificWorldJournal . 2015:2015:816364. td> |
Effect of Zingerone on Glycosylation of Hb levels in different experimental groups: Group-I: normal control; Group-II: diabetic control; Group-III: diabetic rats treated with zingerone (50 mg/kg bw/day); Group-IV: diabetic rats treated with zingerone (100 mg/kg bw/day); Group-V: Diabetic rats treated with glibenclamide 4.5 mg/kg bw/day). Saudi Pharm J . 2018 Dec;26(8):1137-1145. td> |
Effect of Zingerone on NF-κB-p65 levels in different experimental groups: Group-I: normal control; Group-II: diabetic control; Group-III: diabetic rats treated with zingerone (50 mg/kg bw/day); Group-IV: diabetic rats treated with zingerone (100 mg/kg bw/day); Group-V: Diabetic rats treated with glibenclamide 4.5 mg/kg bw/day). Saudi Pharm J . 2018 Dec;26(8):1137-1145. td> |
Effect of Zingerone on TNF-α levels in different experimental groups: Group-I: normal control; Group-II: diabetic control; Group-III: diabetic rats treated with zingerone (50 mg/kg bw/day); Group-IV: diabetic rats treated with zingerone (100 mg/kg bw/day); Group-V: Diabetic rats treated with glibenclamide 4.5 mg/kg bw/day). Saudi Pharm J . 2018 Dec;26(8):1137-1145. td> |
Effects of zingerone on viability of neuroblastoma cell lines. Int J Mol Sci . 2018 Sep 19;19(9):2832. td> |
Effects of zingerone on cell-cycle arrest in BE(2)-M17 cells. Int J Mol Sci . 2018 Sep 19;19(9):2832. td> |
Effect of zingerone on the expressions of cell-cycle-associated proteins and apoptosis in BE(2)-M17 cells. Int J Mol Sci . 2018 Sep 19;19(9):2832. td> |
Effect of zingerone on tumor growth and expressions of cell-cycle-regulatory protein in an in vivo mouse tumor model. Int J Mol Sci . 2018 Sep 19;19(9):2832. td> |